Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp ... fueled by the strong performance of its implantable devices, biologics, accessories and unique surgical ...

Nevro Corp is a medical device company. Its key product is the ... It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a ...

Redwood City, California-based Nevro sells spinal cord stimulation devices for back pain and painful diabetic neuropathy, a complication of diabetes associated with pain or tingling in the arms ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

NEVRO’s HF10 therapy runs at 10 kHz and maintains stable outcomes for chronic trunk pain over more than 2 years of continuous monitoring. Japan’s Ministry of Health granted approval in early 2024 to a ...